Can a doctor be associated with more than one hospital?

Yes, all account users can be associated with multiple hospitals. Please email support@imprimedicine.com if you want to add hospitals or clinics to your account.

Other Questions

Back to Help Center

Why should I order ImpriMed services?

ImpriMed offers a unique precision oncology service that helps you to find the best anticancer drugs for your patients. ImpriMed directly tests a panel of commonly used anticancer drugs on your patients’ live cells in our A2LA accredited lab. In addition, we continually collect patient outcomes that are updated via regular follow-up with pet parents. As our database grows, so does the performance of our anticancer drug response predictions and your ability to develop a personalized treatment plan for each pet patient. So, when you order an ImpriMed service, you are actively contributing to our dataset and helping to improve cancer care for your patients and the ImpiMed user community.

What is the simulated dosing for a certain drug? MTD(maximum tolerated dosing) or metronomic?

Our models don't differentiate between different types of dosing, so they can be viewed as outcomes for standard clinical practice. For instance, if MTD is more common in practice, the models may more closely reflect MTD.

How can I help to advance precision medicine?

The more samples ImpriMed processes and the more clinical outcomes we receive from our customers, the more accurately our AI models are able to determine which drugs will work best for your patients. (Click to read more)

Can we select non-MDR substrate drugs for known or suspected MDR dogs?

Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.

How much research do you have to support your results?

All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.